Short-term Efficacy of Topical Capsaicin Therapy in Severely Affected Fibromyalgia Patients

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2012 Jul 31

PMID 22842953

Citations 15

Authors

Benigno Casanueva

Baltasar Rodero

Covadonga Quintial

Javier Llorca

Miguel A Gonzalez-Gay

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to evaluate the short-term efficacy of topical capsaicin treatment in patients severely affected by fibromyalgia. One hundred and thirty fibromyalgia patients were randomly divided into two groups. The control group, 56 women and 4 men who continued their medical treatment, and the capsaicin group, 70 women who apart from continuing their medical treatment, also underwent topical capsaicin 0.075 % 3 times daily for 6 weeks. At the beginning of the program, there were no significant differences between the two groups in any of the analyzed parameters. At the end of the treatment, there were significant improvements in the capsaicin group in the myalgic score (5.21 vs 3.8, p = 0.02) and global subjective improvement (22.8 vs 5 %, p = 0.001). Six weeks after the end of the treatment, the experimental group showed significant differences in Visual Analogue Scale of depression (5.63 vs 7.35, p = 0.02), Fibromyalgia Impact Questionnaire (67.89 vs 77.7, p = 0.02), role limitations due to emotional problems (36.17 vs 17.2, p = 0.05), Fatigue Severity Scale (6.2 vs 6.6, p = 0.04), myalgic score (3.94 vs 2.66, p = 0.02) and pressure pain threshold (79.25 vs 56.71, p = 0.004). In conclusion, patients severely affected by fibromyalgia can obtain short-term improvements following topical capsaicin 0.075 % treatment three times daily for 6 weeks.

Citing Articles

Electroacupuncture Mitigates TRPV1 Overexpression in the Central Nervous System Associated with Fibromyalgia in Mice.

Anh D, Lin Y Life (Basel). 2025; 14(12.

PMID: 39768313 PMC: 11678918. DOI: 10.3390/life14121605.

Capsaicin: Emerging Pharmacological and Therapeutic Insights.

Petran E, Periferakis A, Troumpata L, Periferakis A, Scheau A, Badarau I Curr Issues Mol Biol. 2024; 46(8):7895-7943.

PMID: 39194685 PMC: 11352336. DOI: 10.3390/cimb46080468.

Bioactive Compounds for Fibromyalgia-like Symptoms: A Narrative Review and Future Perspectives.

Shen C, Schuck A, Tompkins C, Dunn D, Neugebauer V Int J Environ Res Public Health. 2022; 19(7).

PMID: 35409832 PMC: 8998198. DOI: 10.3390/ijerph19074148.

Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update.

Siracusa R, Di Paola R, Cuzzocrea S, Impellizzeri D Int J Mol Sci. 2021; 22(8).

PMID: 33918736 PMC: 8068842. DOI: 10.3390/ijms22083891.

In Vitro Cytotoxic Protective Effect of Alginate-Encapsulated Capsaicin Might Improve Skin Side Effects Associated with the Topical Application of Capsaicin.

Hudita A, Galateanu B, Costache M, Negrei C, Ion R, Iancu L Molecules. 2021; 26(5).

PMID: 33800110 PMC: 7962180. DOI: 10.3390/molecules26051455.

References

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

Hong C, Hsueh T . Difference in pain relief after trigger point injections in myofascial pain patients with and without fibromyalgia. Arch Phys Med Rehabil. 1996; 77(11):1161-6. DOI: 10.1016/s0003-9993(96)90141-0. View

Herpfer I, Lieb K . Substance P and Substance P receptor antagonists in the pathogenesis and treatment of affective disorders. World J Biol Psychiatry. 2003; 4(2):56-63. DOI: 10.3109/15622970309167952. View

Nolano M, Simone D, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy W . Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999; 81(1-2):135-45. DOI: 10.1016/s0304-3959(99)00007-x. View

Staud R . Is it all central sensitization? Role of peripheral tissue nociception in chronic musculoskeletal pain. Curr Rheumatol Rep. 2010; 12(6):448-54. DOI: 10.1007/s11926-010-0134-x. View

Morgenlander J, Hurwitz B, Massey E . Capsaicin for the treatment of pain in Guillain-Barré syndrome. Ann Neurol. 1990; 28(2):199. DOI: 10.1002/ana.410280222. View

Harwood R, Rogers A, Dickinson E, Ebrahim S . Measuring handicap: the London Handicap Scale, a new outcome measure for chronic disease. Qual Health Care. 1994; 3(1):11-6. PMC: 1055176. DOI: 10.1136/qshc.3.1.11. View

Morris V, Cruwys S, Kidd B . Increased capsaicin-induced secondary hyperalgesia as a marker of abnormal sensory activity in patients with fibromyalgia. Neurosci Lett. 1998; 250(3):205-7. DOI: 10.1016/s0304-3940(98)00443-1. View

Ebner K, Muigg P, Singewald G, Singewald N . Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann N Y Acad Sci. 2008; 1144:61-73. DOI: 10.1196/annals.1418.018. View

10.

Wallace D, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman M . Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford). 2001; 40(7):743-9. DOI: 10.1093/rheumatology/40.7.743. View

11.

Krupp L, Larocca N, Steinberg A . The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989; 46(10):1121-3. DOI: 10.1001/archneur.1989.00520460115022. View

12.

Campayo J, Rodero B, Alda M, Sobradiel N, Montero J, Moreno S . [Validation of the Spanish version of the Pain Catastrophizing Scale in fibromyalgia]. Med Clin (Barc). 2008; 131(13):487-92. DOI: 10.1157/13127277. View

13.

Wolfe F, Smythe H, Yunus M, Bennett R, Bombardier C, Goldenberg D . The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990; 33(2):160-72. DOI: 10.1002/art.1780330203. View

14.

Mason L, Moore R, Derry S, Edwards J, McQuay H . Systematic review of topical capsaicin for the treatment of chronic pain. BMJ. 2004; 328(7446):991. PMC: 404499. DOI: 10.1136/bmj.38042.506748.EE. View

15.

Beck A, Epstein N, Brown G, Steer R . An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988; 56(6):893-7. DOI: 10.1037//0022-006x.56.6.893. View

16.

Staud R . Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep. 2002; 4(4):299-305. DOI: 10.1007/s11926-002-0038-5. View

17.

Russell I, Orr M, Littman B, Vipraio G, Alboukrek D, Michalek J . Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994; 37(11):1593-601. DOI: 10.1002/art.1780371106. View

18.

Rivera J, Gonzalez T . The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol. 2004; 22(5):554-60. View

19.

Tan G, Jensen M, Thornby J, Shanti B . Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004; 5(2):133-7. DOI: 10.1016/j.jpain.2003.12.005. View

20.

Bruce B, Fries J . The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003; 1:20. PMC: 165587. DOI: 10.1186/1477-7525-1-20. View